Fifteen major product launches across orthopedics, surgery, cardiovascular and vision supported segment expansion. Electrophysiology improvements and momentum in Surgical Vision and wound closure also bolstered organic growth of 4.3%. J&J anticipates stronger 2026 growth through new product rollouts such as VARIPULSE, ETHICON4000 and OASYS MAX. A planned mid-2027 spin-off of its Orthopaedics franchise into DePuy Synthes aims to sharpen focus on high-growth MedTech markets. J&J’s MedTech segment delivered $34 billion in 2025 sales, marking a 5.4% operational increase. Cardiovascular revenues surged 15.8% to $8.9 billion, driven by the 2022 Abiomed and 2024 Shockwave acquisitions. Sales in China remain under pressure from the volume-based procurement program, while potential tariffs of about $500 million are expected to weigh on 2026 margins. Competitive intensity in key MedTech markets is further challenging pricing power.